AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism
- 21 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (36), 5455-5467
- https://doi.org/10.1038/s41388-021-01943-x
Abstract
Epidemiologic studies in diabetic patients as well as research in model organisms have indicated the potential of metformin as a drug candidate for the treatment of various types of cancer, including breast cancer. To date most of the anti-cancer properties of metformin have, in large part, been attributed either to the inhibition of mitochondrial NADH oxidase complex (Complex I in the electron transport chain) or the activation of AMP-activated kinase (AMPK). However, it is becoming increasingly clear that AMPK activation may be critical to alleviate metabolic and energetic stresses associated with tumor progression suggesting that it may, in fact, attenuate the toxicity of metformin instead of promoting it. Here, we demonstrate that AMPK opposes the detrimental effects of mitochondrial complex I inhibition by enhancing glycolysis at the expense of, and in a manner dependent on, pyruvate availability. We also found that metformin forces cells to rewire their metabolic grid in a manner that depends on AMPK, with AMPK-competent cells upregulating glycolysis and AMPK-deficient cell resorting to ketogenesis. In fact, while the killing effects of metformin were largely rescued by pyruvate in AMPKcompetent cells, AMPK-deficient cells required instead acetoacetate, a product of fatty acid catabolism indicating a switch from sugar to fatty acid metabolism as a central resource for ATP production in these cells. In summary, our results indicate that AMPK activation is not responsible for metformin anticancer activity and may instead alleviate energetic stress by activating glycolysis.Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (RO1CA216882)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (RO1AI131267)
- U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (RO1ES028149)
- U.S. Department of Defense (71138LS)
- American Heart Association (17SDG33661117)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL142152)
This publication has 26 references indexed in Scilit:
- Metformin is synthetically lethal with glucose withdrawal in cancer cellsCell Cycle, 2012
- Cross-Talk between AMPK and mTOR in Regulating Energy BalanceCritical Reviews in Food Science and Nutrition, 2012
- Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer ModelsMolecular Cancer Therapeutics, 2011
- New Users of Metformin Are at Low Risk of Incident CancerDiabetes Care, 2009
- Is it Time to Test Metformin in Breast Cancer Clinical Trials?Cancer Epidemiology, Biomarkers & Prevention, 2009
- AMP-Activated Protein Kinase Induces a p53-Dependent Metabolic CheckpointMolecular Cell, 2005
- Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathwayNature, 2003
- The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling PathwaysOnline Journal of Public Health Informatics, 2002
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001
- Human Cells Lacking mtDNA: Repopulation with Exogenous Mitochondria by ComplementationScience, 1989